Puerto Rico's industrial real estate market in 2026 experiencing a level of capital commitment that would have been difficult to anticipate a decade ago. A convergence of pharmaceutical reshoring pressure, federal incentive alignment, and a workforce with over six decades of advanced manufacturing experience has repositioned the island as one of the most strategically important industrial locations in the U.S. supply chain. At Beyond Commercial Group, we work with leading commercial clients across Puerto Rico's industrial corridors, and the investment activity now underway makes the case more clearly than any market analysis could on its own.
Key Takeaways
- Puerto Rico is the number one bioscience manufacturing hub in the United States, according to the Puerto Rico Industrial Development Company (PRIDCO)
- Eli Lilly announced a $1.2 billion expansion of its Lilly del Caribe campus in Carolina in October 2025, with construction beginning in 2026 and production targeted by end of 2028
- Under Act 60, eligible manufacturing and R&D companies pay a flat 4% corporate income tax compared to 21% on the U.S. mainland
- Industrial and laboratory real estate costs in Puerto Rico run 20 to 35% below comparable U.S. mainland hubs, according to KPMG analysis
A 60-Year Manufacturing Legacy with a New Wave of Investment
Puerto Rico's pharmaceutical and life sciences sector is not a recent development. According to Invest Puerto Rico, the island has served as a critical node in the U.S. drug supply chain for over 60 years, producing more than $50 billion in life sciences products annually for export to more than 120 countries. The infrastructure, regulatory expertise, and workforce that support that output were built over generations.
What is new is the scale and character of reinvestment happening right now, with Global manufacturers committing major capital to expand capacity specifically in Puerto Rico.
The most significant recent announcement came in October 2025, when Eli Lilly revealed a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico. According to the company's press release, the project will transform the PR01 plant into an oral solid dose manufacturing facility, expand the PR05 insulin plant, integrate advanced technologies including dock-to-dock automation and process analytical technology, and add a 9-megawatt cogeneration unit and 2 MW solar field designed to supply up to 85% of the site's energy demand. Construction is scheduled to begin in 2026, with production expected by the end of 2028. The project is part of Lilly's $50 billion U.S. manufacturing commitment and is expected to generate up to 1,000 construction jobs and 100 permanent high-tech manufacturing positions.
That announcement followed Amgen's $650 million manufacturing project in Juncos and ongoing operations from Johnson and Johnson, Bristol-Myers Squibb, and AstraZeneca — a pattern of sustained, large-scale commitment that reflects structural confidence in Puerto Rico's industrial platform.
What is new is the scale and character of reinvestment happening right now, with Global manufacturers committing major capital to expand capacity specifically in Puerto Rico.
The most significant recent announcement came in October 2025, when Eli Lilly revealed a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico. According to the company's press release, the project will transform the PR01 plant into an oral solid dose manufacturing facility, expand the PR05 insulin plant, integrate advanced technologies including dock-to-dock automation and process analytical technology, and add a 9-megawatt cogeneration unit and 2 MW solar field designed to supply up to 85% of the site's energy demand. Construction is scheduled to begin in 2026, with production expected by the end of 2028. The project is part of Lilly's $50 billion U.S. manufacturing commitment and is expected to generate up to 1,000 construction jobs and 100 permanent high-tech manufacturing positions.
That announcement followed Amgen's $650 million manufacturing project in Juncos and ongoing operations from Johnson and Johnson, Bristol-Myers Squibb, and AstraZeneca — a pattern of sustained, large-scale commitment that reflects structural confidence in Puerto Rico's industrial platform.
Why PRIDCO and the Numbers Behind the Advantage
The Puerto Rico Industrial Development Company, or PRIDCO, is the government agency responsible for promoting industrial development and managing the island's portfolio of industrial properties. PRIDCO positions Puerto Rico's advantages across five core dimensions: a highly experienced workforce, U.S. manufacturing jurisdiction, local and federal legal framework alignment, competitive tax incentives, and a geographic position offering access to the U.S., Latin America, and Europe.
On the bioscience side specifically, PRIDCO's data is striking: Puerto Rico is ranked the number one bioscience manufacturing hub in the United States, with 75% of all FDA Class III medical device manufacturers on the island and 30 medical device companies operating there. That concentration of regulated, high-complexity manufacturing reflects not just tax advantages but genuine industrial capability.
On the bioscience side specifically, PRIDCO's data is striking: Puerto Rico is ranked the number one bioscience manufacturing hub in the United States, with 75% of all FDA Class III medical device manufacturers on the island and 30 medical device companies operating there. That concentration of regulated, high-complexity manufacturing reflects not just tax advantages but genuine industrial capability.
Key Cost Differentials Versus Mainland U.S. Manufacturing
- Labor: average hourly wages for pharmaceutical and medical device manufacturing workers run 30 to 40% lower than in comparable mainland hubs including New Jersey, Massachusetts, and North Carolina, per U.S. Bureau of Labor Statistics and DDEC data
- Taxes: Act 60 eligible manufacturers pay 4% corporate income tax with no additional state income tax, versus 21% federal plus applicable state rates on the mainland
- Industrial real estate: lab and industrial space runs 20 to 35% below equivalent space in major U.S. manufacturing corridors, according to KPMG estimates
- Regulatory jurisdiction: all goods produced in Puerto Rico carry "Made in U.S.A." designation and operate under full FDA regulatory oversight thereby eliminating the compliance risk and geopolitical uncertainty that accompanies offshore manufacturing alternatives
That combination of mainland regulatory alignment with an emerging-market cost structure is what makes Puerto Rico's industrial case structurally different from other cost-reduction approaches.
Where Industrial Demand Is Concentrated
Puerto Rico's industrial and life sciences activity spans the island rather than concentrating solely in San Juan. Understanding the geographic distribution of that demand matters for anyone evaluating where to place industrial real estate exposure. Given the immense shortage of warehouses across the island, it is more important than ever to work with a real estate broker, like us, at Beyond Commercial Group to get insider knowledge of off-market warehousing opportunities for lease or for sale.
Key Industrial Zones Across Puerto Rico
- Carolina: adjacent to Luis Muñoz Marín International Airport and the site of Lilly del Caribe's major ongoing expansion; logistics and air freight access make this one of the island's most active industrial corridors
- Juncos and the eastern interior: site of Amgen's $650 million manufacturing project. The Juncos corridor has established itself as a center for large-scale biopharmaceutical production
- Barceloneta and the north coast: one of Puerto Rico's most established pharmaceutical manufacturing zones, with existing infrastructure, a trained workforce, and multiple industrial parks
- Aguadilla and the northwest: home to Rafael Hernandez Airport, which operates the longest runway in the Caribbean at 11,702 feet. The Aguadilla airport supports top aerospace manufacturers including Honeywell Aerospace and Lufthansa Technik Puerto Rico.
Aerospace and Beyond: Industrial Diversification
Life sciences dominate Puerto Rico's industrial real estate narrative, but PRIDCO's mandate covers a broader set of sectors that matter to industrial real estate buyers and tenants.
Puerto Rico's aerospace sector benefits from the same workforce and infrastructure advantages as life sciences. Honeywell Aerospace and Lufthansa Technik Puerto Rico both operate on the island, drawn in part by the engineering talent pool and PRIDCO's reported 100% compliance rate with defense segment criteria in the aerospace sector. Aguadilla Airport's runway infrastructure supports MRO and logistics operations that few Caribbean locations can match.
The food and agriculture sector contributes $869 million to Puerto Rico's GDP with 11,800 workers in food manufacturing, according to PRIDCO data, with 90% of agribusiness income exempt from income taxes under applicable incentive programs.
Puerto Rico's aerospace sector benefits from the same workforce and infrastructure advantages as life sciences. Honeywell Aerospace and Lufthansa Technik Puerto Rico both operate on the island, drawn in part by the engineering talent pool and PRIDCO's reported 100% compliance rate with defense segment criteria in the aerospace sector. Aguadilla Airport's runway infrastructure supports MRO and logistics operations that few Caribbean locations can match.
The food and agriculture sector contributes $869 million to Puerto Rico's GDP with 11,800 workers in food manufacturing, according to PRIDCO data, with 90% of agribusiness income exempt from income taxes under applicable incentive programs.
FAQs
How does Act 60 benefit manufacturers specifically?
Act 60 covers multiple incentive categories for manufacturing and R&D operations in Puerto Rico. Eligible companies access a 4% flat corporate income tax rate, exemptions on dividends and interest from qualified activities, and additional incentives tied to job creation and capital investment. The Puerto Rico Department of Economic Development and Commerce (ddec.pr.gov) administers the program, and PRIDCO coordinates with DDEC on industrial site identification and incentive navigation for companies evaluating the island.
Does Puerto Rico's U.S. territory status simplify industrial transactions for mainland buyers?
Yes. Puerto Rico operates under U.S. federal law, uses the U.S. dollar, and follows standard U.S. property transaction processes. There are no foreign transaction complications, and financing is available through standard U.S. commercial lending channels. For mainland buyers and tenants, the process is familiar while the cost structure is materially different.
Invest in Puerto Rico's Industrial Real Estate Market
We represent commercial clients across Puerto Rico's industrial, office, and mixed-use sectors. Our understanding of Act 60 implications, PRIDCO's property portfolio, local regulatory frameworks, and off-market inventory across the island's manufacturing corridors gives our clients access to opportunities that the public market does not surface.
Reach out to us to learn more about how we work with industrial and commercial real estate investors in Puerto Rico.
Reach out to us to learn more about how we work with industrial and commercial real estate investors in Puerto Rico.
Disclaimer:
This article is intended for informational purposes only and does not constitute financial, legal, or real estate advice. Although every effort has been made to ensure accuracy, market conditions and regulations may change, and the data referenced may not reflect the latest updates. Readers should consult qualified professionals—such as real estate agents, attorneys, and financial advisors—before making any property-related decisions based on the information provided here. The author and publisher assume no responsibility or liability for any errors, omissions, or decisions made in reliance on this content.
This article is intended for informational purposes only and does not constitute financial, legal, or real estate advice. Although every effort has been made to ensure accuracy, market conditions and regulations may change, and the data referenced may not reflect the latest updates. Readers should consult qualified professionals—such as real estate agents, attorneys, and financial advisors—before making any property-related decisions based on the information provided here. The author and publisher assume no responsibility or liability for any errors, omissions, or decisions made in reliance on this content.
